Terms: = Bone cancer AND MLLT10, P55197, 8028, ENSG00000078403, AF10 AND Treatment
4 results:
1. Cooperation of MLL/af10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.
Fu JF; Liang ST; Huang YJ; Liang KH; Yen TH; Liang DC; Shih LY
Int J Cancer; 2017 Mar; 140(5):1159-1172. PubMed ID: 27859216
[TBL] [Abstract] [Full Text] [Related]
2. Abrogation of MLL-af10 and CALM-af10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
Chen L; Deshpande AJ; Banka D; Bernt KM; Dias S; Buske C; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Leukemia; 2013 Apr; 27(4):813-22. PubMed ID: 23138183
[TBL] [Abstract] [Full Text] [Related]
3. Acute leukemia with PICALM-mllt10 fusion gene: diagnostic and treatment struggle.
Savage NM; Kota V; Manaloor EJ; Kulharya AS; Pierini V; Mecucci C; Ustun C
Cancer Genet Cytogenet; 2010 Oct; 202(2):129-32. PubMed ID: 20875875
[TBL] [Abstract] [Full Text] [Related]
4. MLL/af10(OM-LZ)-immortalized cells expressed cytokines and induced host cell proliferation in a mouse bone marrow transplantation model.
Fu JF; Hsu CL; Shih LY
Int J Cancer; 2010 Apr; 126(7):1621-9. PubMed ID: 19711340
[TBL] [Abstract] [Full Text] [Related]
